Latest News for: moa

Edit

Anti-CD152 Antibody Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight ...

GetNews 21 Aug 2025
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anti-CD152 Antibody Market ... Some of the key takeaways from the Anti-CD152 Antibody Pipeline Report. ... RC58 ... 1.
Edit

Paroxysmal Nocturnal Hemoglobinuria Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, ...

GetNews 21 Aug 2025
DelveInsight’s, “Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Haemoglobinuria pipeline landscape ... Pozelimab ... NV.
Edit

IgA Nephropathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 21 Aug 2025
DelveInsight's, "IgA Nephropathy Pipeline Insight, 2025," report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape ... It further highlights the inactive pipeline products in this space ... City.
Edit

Acne Vulgaris Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved ...

GetNews 21 Aug 2025
The Acne Vulgaris Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase ... Some of the key takeaways from the Acne Vulgaris Pipeline Report. ... (Nasdaq.
Edit

Non-Hodgkin’s Lymphoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 21 Aug 2025
DelveInsight’s, “Non-Hodgkin Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape ... Bristol Myers Squibb ... Ryvu Therapeutics ... NV.
Edit

Primary Hyperoxaluria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | ...

GetNews 21 Aug 2025
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market ... Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report. ... 1 ... 2.
Edit

Esophageal Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 21 Aug 2025
DelveInsight, “Esophageal Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Esophageal Cancer pipeline landscape ... Learn more about our innovative pipeline today! @ ... City.
Edit

Gastrointestinal Stromal Tumors Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, ...

GetNews 21 Aug 2025
DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape ... Nilotinib. Novartis ... City.
Edit

Parkinson’s Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight ...

GetNews 20 Aug 2025
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market ... In June 2025, Roche (SIX. RO, ROG; OTCQX ... KM-819. FAScinate Therapeutics ... NA.
Edit

Interstitial Cystitis Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights ...

GetNews 20 Aug 2025
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Cystitis Market ... Some of the key takeaways from the Interstitial Cystitis Pipeline Report. ... 1 ... 2.
Edit

COPD Clinical Trials Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight ...

GetNews 20 Aug 2025
The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase ... ANZCTR12624001140549p) ... (NASDAQ ... Benralizumab ... Amgen.
Edit

Anaplastic Thyroid Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, ...

GetNews 19 Aug 2025
DelveInsight’s, “Anaplastic Thyroid Cancer Pipeline Insight 2025,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape ... Takeda ... HLX208 ... About Us ... Media Contact.
Edit

Chronic Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, ...

GetNews 19 Aug 2025
DelveInsight’s, “Chronic Myeloid Leukaemia Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Myeloid Leukaemia pipeline landscape ... Kartos Therapeutics ... About Us ... Email.
Edit

Cystic Fibrosis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, ...

GetNews 19 Aug 2025
DelveInsight’s, “Cystic fibrosis Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Cystic fibrosis pipeline landscape ... The study will be run in two parts ... VX-522 ... KB407 ... SPL23.
Edit

Acquired Hemophilia A Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA ...

GetNews 19 Aug 2025
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acquired Hemophilia A Market ... Some of the key takeaways from the Acquired Hemophilia A Pipeline Report ... 1 ... 2.

Article Search

tools
×
×
×
×